Share this page: More
 

Craig W. Hendrix

Hendrix

Department Affiliation: Primary: Medicine, Division of Clinical Pharmacology; Secondary: Pharmacology and Molecular Sciences, Division of Infectious Diseases, Epidemiology, Bloomberg School of Public Health
Degree: M.D., Georgetown University School of Medicine
Rank: Professor
Telephone Number: 410-955-9707
Fax Number: 410-955-9708
E-mail address: chendrix@jhmi.edu
School of Medicine Address: Blalock 569, 600 N. Wolfe Street, Baltimore, MD 21287 

 

Current research focuses on prevention of HIV infection


Research focuses on clinical pharmacology of HIV prevention through development of drugs for pre-exposure prophylaxis with an emphasis on: (1) development of methods to assess distribution of topical HIV microbicides, CD4 cells, and HIV in the sites of sexual transmission; (2) PK-PD models of pre-exposure antiretroviral HIV prophylaxis; (3) development of methods to understand the compartmentalization of antiretroviral drugs and HIV within the male genital tract. Other research involves HIV pharmacology, fungal chemoprevention, and drug-drug interactions.

Representative Publications:

  • Landovitz, R.J., Li, S., Eron, J.J., Grinsztejn, B., Dawood, H., Liu, A.Y., Magnus, M., Hosseinipour, M.C., Panchia, R., Cottle, L., Chau, G., Richardson, P., Marzinke, M.A., Eshleman, S.H., Kofron, R., Adeyeye, A., Burns, D., Rinehart, A.R., Margolis, D., Cohen, M.S., McCauley, M., Hendrix, C.W. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: HPTN 077. Lancet HIV 2020 (accepted).
  • Shieh, E., Marzinke, M.A., Fuchs, E.J., Hamlin, A., Bakshi, R., Aung, W., Breakey, J., Poteat, T., Brown, T., Bumpus, N.N., Hendrix, C.W. Transgender Women on Oral HIV Pre-exposure Prophylaxis Have Significantly Lower Tenofovir and Emtricitabine Concentrations when also taking Estrogen When Compared to Cisgender Men. J Int AIDS Soc 22:e25405, 2019. Pub Med Reference
  • Hendrix, C.W., Andrade, A., Bumpus, N.N., Kashuba, A.D., Marzinke, M., Moore, A., Anderson, P.L., Bushman, L.R., Fuchs, E., Wiggins, I., Radebaugh, C., Prince, H.A., Bakshi, R., Wang, R., Richardson, P., Shieh, E., McKinstry, L., Li, X., Donnell, D., Elharrar, V., Mayer, K., Patterson, K.B. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine after Directly Observed Dosing in Healthy Volunteers to establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retrovir 32(1):32-43, 2016. Pub Med Reference
  • Hendrix, C.W., Chen, B.A., Guddera, V., Hoesley, C., Justman, J., Nakabiito, C., Salata, R., Soto-Torres, L., Patterson, K., Minnis, A.M., Gandham, S., Gomez, K., Richardson, B.A., Bumpus, N.N.  Pharmacokinetic cross-over study in women comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other anatomic compartments (MTN-001).  PLoS One 8(1):e55013, 2013.  Pub Med Reference
  • Ojeda, V.D., Amico, K.R., Hughes, J.P., Wilson, E., Holtz, T.H., Chitwarakorn, A., Grant, R.M., Dye, B., Bekker, L.G., Mannheimer, S., Marzinke, M.A., Hendrix, C.W. Low Disclosure of PrEP nonadherence and HIV risk behaviors associated with poor HIV PrEP adherence in the HPTN 067/ADAPT Study. JAIDS 82(1):34-40, 2019. Pub Med Reference
  • Carballo-Dieguez, A., Giguere, R., Lentz, C., Dolezal, C., Fuchs, E.J., Hendrix, C.W. Rectal Douching Practices Associated with Anal Intercourse: Implications for the Development of a Behaviorally Congruent HIV-Prevention Rectal Microbicide Douche. AIDS Behav. 23(6):1484-1493, 2019. Pub Med Reference
  • Robinson, J.A., Marzinke, M.A., Fuchs, E.J., Bakshi, R.P., Radebaugh, C.L., Spiegel, H.M.L., Coleman, J.S., Rohan, L.C., Hendrix, C.W. Comparison of the pharmacokinetics and pharmacodynamics of single-dose tenofovir vaginal film and gel formulation (FAME-05). JAIDS 77(2):175-182, 2018.  Pub Med Reference
  • Weld, E.W.*, Hiruy, H.*, Guthrie, K.M., Fava, J.L., Vargas, S.E., Buckheit, K., Buckheit, R., Spiegel, H., Breakey, J., Fuchs, E.J., Hendrix, C.W. A Comparative Pre-Phase I Study of the Impact of Gel Vehicle Volume on Distal Colon Distribution, User Experience, and Acceptability. AIDS Res Hum Retrovir 33(5):440-447, 2017. *Co-First authors. Pub Med Reference
  • Robinson, J.A., Marzinke, M.A., Bakshi, R.P., Fuchs, E.J., Radebaugh, C.L., Aung, W., Spiegel, H.M.L., Coleman, J.C., Rohan, L.C., Hendrix, C.W. Comparison of dapivirine vaginal gel and film formulation pharmacokinetics and pharmacodynamics (FAME 02B). AIDS Res Hum Retrovir 33(4):339-346, 2017. Pub Med Reference
  • Lu, Y., Goti, V., Chaturvedula, A., Haberer, J., Fossler, M., Sale, M., Bangsberg, D., Baeten, J., Celum, C., Hendrix, C.W. Population pharmacokinetics of tenofovir in HIV-1 uninfected members of sero-discordant couples and effect of dose reporting methods. Antimocrob Agen Chemother 60:5379-5386, 2016. Pub Med Reference
  • Coleman, J., Fuchs, E.J., Aung, W.S., Marzinke, M.A., Bakshi, R.P., Spiegel, H.M.L., Robinson, J.R., Hendrix, C.W. Feasibility of radiolabeled small molecule permeability as a quantitative measure of microbicide candidate toxicity. Contraception 93(4):331-336, 2016. Pub Med Reference
  • van der Straten, A., Brown, E.R., Marrazzo, J.M., Chirenje, M.Z., Liu, K., Gomez, K., Marzinke, M.A., Piper, J.M., Hendrix, C.W. MTN-003 VOICE Protocol Team. Divergent Adherence Estimates with Pharmacokinetic and Behavioral Measures in the MTN-003 (VOICE) Study. J Internat AIDS Soc 19(1):20642, 2016. Pub Med Reference

 


Other Graduate programs Dr. Hendrix participates in: